ArticleStem cells and development2020
Re: "Exosomes Derived from Bone Marrow Mesenchymal Stem Cells as Treatment for Severe COVID-19" by Sengupta et al.
Article in Stem cells and development, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Effect of mesenchymal stromal cells-derived extracellular vesicles as a treatment to heal diabetic wounds: A meta-analysis.International wound journal · 2023Pooled it
- Beyond Extracellular Vesicle (EV) Hype: Practical Solutions and Remaining Hurdles in EV Research, Manufacturing, and Clinical Translation.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Immunomodulatory effects and clinical application of exosomes derived from mesenchymal stem cells.World journal of stem cells · 2025Review
- Harnessing exosomes for advanced osteoarthritis therapy.Nanoscale · 2024Review
- Extracellular vesicles as human therapeutics: A scoping review of the literature.Journal of extracellular vesicles · 2024Article
- Meet changes with constancy: Defence, antagonism, recovery, and immunity roles of extracellular vesicles in confronting SARS-CoV-2.Journal of extracellular vesicles · 2022Review
- Tissue repair strategies: What we have learned from COVID-19 in the application of MSCs therapy.Pharmacological research · 2022Review
- Stem cell therapy for COVID-19 pneumonia.Molecular biomedicine · 2022Review
- Hyper-inflammatory responses in COVID-19 and anti-inflammatory therapeutic approaches.BMB reports · 2022Article
- Mesenchymal Stromal Cell Secretome for the Treatment of Immune-Mediated Inflammatory Diseases: Latest Trends in Isolation, Content Optimization and Delivery Avenues.Pharmaceutics · 2021Review
- Extracellular Vesicle-Based Therapy for COVID-19: Promises, Challenges and Future Prospects.Biomedicines · 2021Review
- Mesenchymal stem cell-based therapy and exosomes in COVID-19: current trends and prospects.Stem cell research & therapy · 2021Review
- Updates on clinical trials evaluating the regenerative potential of allogenic mesenchymal stem cells in COVID-19.NPJ Regenerative medicine · 2021Review
- Mesenchymal Stem Cell-Derived Exosome Therapy of Microbial Diseases: From Bench to Bed.Frontiers in microbiology · 2021Review
- Functional assays to assess the therapeutic potential of extracellular vesicles.Journal of extracellular vesicles · 2020Review
- Review
- Response to Lim et al. re: "Exosomes Derived from Bone Marrow Mesenchymal Stem Cells as Treatment for Severe COVID-19".Stem cells and development · 2020Article
- Cell-Free Therapies: Novel Approaches for COVID-19.Frontiers in immunology · 2020Review
Corrections and comments
- Comment on
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.